🇺🇸 2026-11-22 · EORTC-NCI-AACR Symposium (ENA 2026), press release

A daily pill plus chemotherapy held pancreatic cancer in check for over a year in an early trial

In an early trial with 61 people whose pancreatic cancer had spread, a new pill given alongside standard chemotherapy shrank tumours in six out of ten. The lead doctor is at Memorial Sloan Kettering Cancer Center in New York, and the results were presented on 20 November in Barcelona.

A calm hospital laboratory in the morning, with a microscope, glass vials and small white tablets on the bench.
AI-generated illustration

Pancreatic cancer is one of the hardest cancers to treat. More than half of patients find out only after it has spread to other organs. On standard chemotherapy most live around 8 to 11 months, and tumours usually start growing again after 5 or 6 months. Only about 3 in 100 people with spread disease are alive five years later.

More than 90% of these tumours carry a mutation in the RAS genes. The new drug, daraxonrasib, is a pill aimed at RAS proteins. Patients take 200 milligrams once a day.

In the RMC-GI-102 trial, Dr Wungki Park and his team gave the pill together with two chemotherapy drugs, gemcitabine and nab-paclitaxel. All 61 patients had metastatic pancreatic cancer that had not yet been treated. They were followed for a median of 18.3 months.

Tumours shrank or disappeared in 60.7% of patients. In 8.2%, about one in 12, they could no longer be detected on scans. The disease stopped advancing in 90.2%. The median time before the cancer worsened was 12.8 months, and 76.6% of patients were alive after one year. "Pancreatic cancer remains one of the most challenging cancers to treat," Park said.

The treatment is not gentle. The most common side effects were rash, diarrhoea, fatigue and a drop in some blood cells caused by the chemotherapy. 5% of patients stopped treatment because of side effects from the new drug.

The limits matter. This is an early trial, and no group received chemotherapy alone. Park himself notes that "patients were not compared with patients receiving chemotherapy alone". So comparing with older results does not yet prove that people will live longer. The study was sponsored by Revolution Medicines, the company developing the drug. The answer will come from a large global trial, RASolute-303, which compares the pill, alone and with chemotherapy, against standard chemotherapy.

Professor Elena Garralda, chair of the symposium, who was not involved in the study, sees a wider point: "Importantly, it shows that RAS-targeted therapies can be combined with existing treatments." RAS mutations also drive some lung, bowel and gynaecological cancers, but each would need its own trials.

The results were presented on 20 November 2026 at the 38th EORTC-NCI-AACR Symposium in Barcelona. For now they come from a conference presentation, not a peer-reviewed journal article.

Sources

Told by Aurora, a language model. Every story is reviewed by a person before publication.

More stories

Good news on Telegram · Follow

A representative website for your business

GOODNEWS is a project of ECOMM, Ruse, Bulgaria. We build representative websites for companies and for people whose name is their business.

Visit ECOMM

Give someone good news

The name and the words stay in the link only. They never pass through our server.